AGORACOM News Flash

AGORACOM CONFERENCE UPDATE

12 More Companies Added To Schedule For Dec 3 & 4. (See Schedule)
Keynote Speakers Include Peter Grandich, Eric Coffin (See Speakers)
Workshop Presentations Added To Thursday Schedule
Investors from over 45 Countries Have Visited
Conference Begins 2 Weeks From Today!

Looking forward to seeing all of you there gang. Registration is free for investors. AGORACOM Members register with just one click. Non-members takes less than 60 seconds. Register here (see form on right hand side)

Message: NEWS - Haemacure to Present at the BioInternational Convention - The Global Event for Biotechnology - at the San Diego Convention Centre, California, from June 17 - 20, 2008

AGORACOM

Rank: [?]

President

Points: [?]

11204

Rating: [?]

Votes: 29 Score: 4.0

Currently 4.0/5 Stars.

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

NEWS - Haemacure to Present at the BioInternational Convention - The Global Event for Biotechnology - at the San Diego Convention Centre, California, from June 17 - 20, 2008

posted on Jun 13, 08 01:32PM

MONTREAL, June 13 - Haemacure Corporation (TSX : HAE), a
Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, announced today that Joseph Galli, Chairman and Chief Executive Officer, will present Haemacure and give an update on the Company's major milestone achievements at the Bio International Convention - The Global Event for Biotechnology. The presentation will take place on Thursday, June 19th, at 1:30 pm (PDT), in Room 3, of the San Diego Convention Centre.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing
high-value human plasma-derived protein products for commercialization.
Haemacure's research and development effort is driven by its proprietary
plasma protein extraction technology to develop next-generation products,
including surgical hemostats. Haemacure's lead product candidate,
Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/Phase
III clinical trials during the first quarter of 2009. Haemacure's second
product candidate is thrombin, a component of its fibrin sealant, now in
preclinical stage. Follow-on development will focus on surgical hemostats,
wound healing, adhesion prevention, regenerative medecine, drug delivery and
combination with biomaterials. Haemacure has discovered eleven additional
specialty proteins and enzymes in one if its two plasma fractions and seeks to
advance these proteins and enzymes through partnerships with pharmaceutical
and biotechnology companies. Haemacure operates offices in Sarasota, Florida
through a wholly-owned subsidiary. The Corporation is traded under stock
symbol HAE on the TSX.